The progressive decrease in stroke mortality observed in Western countries, in the last decades, and the subsequent increase of survivors with residual impairments and disabilities ([@b73]), have been accompanied by a growing interest in factors that could interfere with functional outcome and quality of life (QoL). In light of this, a crucial role is played by post-stroke depression (PSD).

In particular, mood depression is considered as the strongest predictor of QoL in stroke survivors ([@b46]; [@b47]). Moreover, PSD is associated with an increased disability ([@b76]; [@b37]; [@b69]; [@b49]; [@b67]), increased cognitive impairment ([@b43]), increased mortality, both on short and long term ([@b60]; [@b75]; [@b40]; [@b89]), increase risk of falls ([@b42]) and, finally, with worse rehabilitation outcome ([@b78]; [@b64], [@b63]; [@b84]; [@b29]). Conversely, the absence of PSD in young adults is a significant predictor of the ability to return to work ([@b62]). Moreover, an improvement of depressive symptoms has been associated with a better functional recovery ([@b16]).

In spite of the relative large number of papers available on PSD, it is surprising to note that the attention of authors has been focused on epidemiological features and impact of PSD both on functional outcome and QoL than on possible therapeutic approaches.

This review concerns a literature evaluation on epidemiological and therapeutic aspects of PSD. Relevant articles related to depression and cerebrovascular diseases selected from computer-based search have been examined using the Medline database from 1975 to August 2007.

Epidemiological dimension and methodological problems
=====================================================

Today, in spite of the abundant literature available on this topic, it is still difficult to define the real prevalence rate of PSD, essentially because of the weak concordance across studies. This relevant variability arises not only from methodological problems of the investigations (differences in study populations and the timing of assessments) but also from the complexity in recognition, assessment, and diagnosis of depression.

In fact, as shown in the [Table 1](#tbl1){ref-type="table"}, there is a large variability of diagnostic tools used for the detection of PSD. In fact, while most of the studies based the diagnosis on cutoff score in different rating scales, others followed a structured interview and the diagnostic standards defined by DSM (Diagnostic and statistical manual of mental disorders)-III, III-R, and IV, and some studies even based their assessment only on clinical findings.

###### 

Prevalence of PSD according to time and setting of evaluation

  ---------------------------------------------------------------------------------------------------------------------
  Authors                  n       Population                      Country       Time        Criteria             \%
  ------------------------ ------- ------------------------------- ------------- ----------- -------------------- -----
  Folstein et al 1977      20      Rehab hosp                      USA           1 m         HDRS/PSE             45

  Robinson et al 1981      18      hospital-based                  USA           \<1 m       HDRS, ZSRDS          61

  Feibel et al 1982        91      outpatient                      USA           6 m         Nursing evaluation   26

  Robinson et al 1983      103     hospital-based                  USA           1 m         HDRS, PSE,DSM-III    47

  [@b78]                   64      Rehab hosp                      CND           \<2 m       ZSRDS                47

  Ebrahim et al 1987       149     hospital-based                  UK            6 m         GHQ                  23

  Wade et al 1987          379\    Community                       UK            \<1 m\      WDI                  22\
                           377\                                                  6 m\                             20\
                           348                                                   12 m                             18

  Eastwood et al 1989      87      Rehab hosp                      CND           21 d- 6 m   HDRS, GDS            50

  Finset et al 1989        42      Rehab hosp                      Norway        6 m         GCRD                 36

  Malec et al 1990         20      Rehab hosp                      USA           1 m         HDRS                 35

  Morris et al 1990        99\     rehab hosp                      AU            2 m\        MADRS/CIDI           35\
                           56                                                    15 m                             12

  Parikh et al 1990        63      hospital-based\                 USA           \<1 m\      HDRS, PSE,DSM-III    39\
                                   hospital-based                                2 y                              39

  [@b25]                   205     hospital-based                  USA           \<1 m       HDRS, PSE,DSM-III    41

  House et al 1991         89\     community                       UK            1 m\        PSE, DSM-III         23\
                           119\                                                  6 m\                             20\
                           112                                                   12 m                             16

  [@b74]                   18      rehab hosp                      USA           1.5 m       BDI, DSM-III         72

  Astrom et al 1993        80\     hospital-based                  SW            2 m\        DSM-III              25\
                           77\                                                   3 m\                             31\
                           73\                                                   1 y\                             16\
                           57\                                                   2 y\                             19\
                           49                                                    3 y                              29

  [@b76]                   91      rehab hosp                      USA           7 m         DSM-III              40

  Andersen et al 1994      285\    hospital-based                  DK            1 m\        HDRS                 21\
                           285                                                   1 y                              41

  Burvill et al 1995       294     community                       AU            4 m         PSE, DSM-III         23

  Diamond et al 1995       14      rehab hosp                      USA                       GDS                  36

  [@b30]                   130     rehab hosp                      Belgium       1 m         HDRS, MADRS          37

  Wilkinson et al 1997     96      community                       UK            5 y         HADS                 36

  Ng et al 1995            52      rehab hosp                      Singapore     \<1 m       DSM-III-R            55

  [@b37]                   150\    hospital-based                  CND           3 m\        MADRS                27\
                           133                                                   1 y                              22

  Pohjasvaara et al 1998   277\    hospital-based                  FIN           3 m\        DSM-III-R            40\
                           276                                                   15 m                             45

  [@b62]                   71      outpatient                                    \>1 y       MADRS/DSM-III        48

  [@b49]                   321\    community                       FIN           3 m\        BDI                  47\
                           311                                                   12 m                             47

  [@b45]                   82      hospital-based                  Hungary       1 w         BDI                  15

  Gainotti et al 1999      153\    rehab hosp                      Italy         2 m\        HDRS                 32\
                           153                                                   4 m                              60

  [@b43]                   106     rehab hosp                      FIN           3 m         PSE, DSM-IIII-R      53

  [@b64]                   470     rehab hosp                      Italy         1.5 m       HDRS                 27

  [@b84]                   85      rehab hosp                      Netherlands   20--40 d    DSM-III-R            35

  [@b12]                   89      hospital-based                  FIN           \<1 m       BDI                  27

  [@b29]                   243     rehab hosp                      USA           \<1 m       GDS                  13

  Vataja et al 2001        275     outpatient                      FIN           3 m         PSE, DSM-IIII-R      40

  Tang et al 2002          157     rehab hosp                      China         1 m         DSM-III-R            17

  Aben et al 2002          154\    hospital-based                  Netherlands   1 m\        DSM-IV\              22\
                           154                                                   2 y         DSM-IV               39

  Eriksson et al 2004      15747   community                       Sweden        3 m         Self reported        14

  Cassidy et al 2004       50      rehab hosp                      Ireland       6 m         DSM-IV, HDRS         20

  [@b57]                   195     rehab hosp                      USA           \<1 m       DSM-III-R            36

  [@b87]                   110\    outpatient                      France        6 m\        MADRS                43\
                           96\                                                   1 y\                             36\
                           71\                                                   2 y\                             24\
                           73                                                    3 y                              18

  [@b86]                   70      outpatient                      FIN           3 m         PSE, DSM-IIII-R      37

  Naess et al 2005         196     outpatient                      Norway        6 y         MADRS                29

  Paul et al 2006          441     outpatient                      Australia     5 y         IDAS                 17

  Hackett et al 2006       739     community                       NZ            6 m         GHQ                  27

  Jia et al 2006           5825    hospital-based, retrospective   USA           1 y         clinical             41

  [@b65]                   1064\   hospital-based                  Italy         1 m\        BDI, DSM-IV          22\
                           821                                                   9 m                              36

  [@b82]                   125\    hospital-based                  Australia     1 m\        HADS\                16\
                           125                                                   3 m         HADS                 21

  van de Port et al 2007   165     outpatient                      Netherlands   3 y         CES-D                19

  [@b54]                   149     outpatient                      Sweden        20 m        DSM-III-R            34

  [@b14]                   164\    hospital-based\                 Australia\    3 m\        DSM-III-R\           12\
                           164     outpatient                      Australia     15 d        DSM-IV               21
  ---------------------------------------------------------------------------------------------------------------------

**Abbreviations:** d, days; m, months; y, years; BDI, Beck Depression Inventory; CES-D, Centre for Epidemiologic Studies Depression Scale; CIDI, Composite International Diagnostic Interview; DSM, Diagnostic and Statistical Manual of Mental Disorder; GCRD, Global Clinical Rating of Depressed mood; GDS, Geriatric Depression Scale; GHQ, General Health Questionnaire; HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery Asberg Depression Rating Scale; IDAS, Irritability, Depression and Anxiety Scale; PSE, Present State Examination; WDI, Wakefield Depression inventory; ZSRDS, Zung Self Rating Depression Scale.

Moreover, assessment of depression in stroke survivors may be often laborious and the risk of inappropriate diagnosis (under- or overdiagnosing) is high ([@b25]). In fact, PSD may not only be overdiagnosed because of somatic symptoms caused by medical illness, but also underdiagnosed, particularly in patients with cognitive impairment. Another problem, as observed by [@b74], may be the inadequacy of physicians without a proper psychiatric training ([@b74]). The correct attribution of somatic symptoms (psychomotor retardation, and disturbances in appetite, sleep, and sexual interest) to either PSD or stroke is a very relevant problem, because such symptoms may affect rating scales, as Hamilton Depression Rating Scale (HDRS), Montgomery Asberg Depression Rating Scale (MADRS), or Beck Depression Inventory (BDI), and also because they are among DSM criteria. It is important to remember that rating scales were designed to measure depression severity in primary depressive illness, rather than to diagnose depression, in particular for depression in comorbidity. Furthermore, DSM criteria for classification of disorders, (temporal criteria, in particular)are not always satisfied for dysthymia and major depression. So, we found cases diagnosed as major depression even in reports on PSD in settings characterized by short hospital stay, such as stroke units ([@b45]; [@b12]). Additionally, other relevant points, as evaluation-time after stroke (acute vs. chronic patients) and variability of the study setting (in-patients, outpatients, patients bedridden in rehabilitation structures, community), minimize the possibility of a generalization. Lastly, the problem of aphasia should be kept in mind. The exclusion of aphasic patients, because of the evident difficulty in evaluating depressive symptoms, reported in several of studies examined, may be an important confounding variable ([@b15]). However, there is no concordance on frequency of PSD in aphasics, observed either in low (15%) ([@b22]), in middle (24%) ([@b50]) and in high percentage (70% at 3 months and 62% at 12 months after stroke) of cases ([@b44]).

A recent meta-analysis, evaluating data from studies conducted between 1977 and 2002, estimated the pooled frequency at 33% (95% confidence interval, 29% to 36%) ([@b35]), even if with relevant differences across studies. In particular, the pooled estimate from the population-based studies was equal in the acute and medium-term phases (33%), with a slight increase to 34% in the long-term phase of recovery after stroke. Moreover, there were only slight differences in the pooled frequencies in the hospital-based (acute 36%, medium-term 32%, and long-term 34%) and rehabilitation-based studies (acute 30%, medium 36%, and long-term 34%) over time.

Studies available after the publication of that report confirmed that PSD is generally observed in nearly one third of cases ([@b86]; [@b87]; [@b65]; [@b54]; [@b82]). However, a certain degree of variability in the percentages was observed in those reports, too. In particular, the percentage of depression observed in the Sidney Stroke Study was lower than in the previous ones ([@b14]). Moreover, recent longitudinal studies observed not only that frequency PSD increases in prevalence over the initial weeks post-stroke, in particular within three months from stroke, despite an improvement in disability ([@b8]; [@b1]; [@b65]), but also that patients with early onset PSD were not necessarily affected later and vice versa, indicating the dynamic nature of PSD in the early stages.

Only few epidemiological data on vascular depression are available today. Vascular depression is a new diagnostic concept based on hypothesis that chronic ischemic damage is an important cause of depression in the elderly. This concept initially emerged from the finding that patients with late-onset depression had higher rate of encephalomalacia or hyperintensities observed with magnetic resonance imaging (MRI) compared with patients with early-onset depression ([@b38]), and was later formulated by Alexopoulos and coworkers in 1997. These authors hypothesized that cerebrovascular disease can predispose, precipitate, or perpetuate a depressive syndrome in older adults ([@b4]). Affected individuals display more apathy, retardation, and lack of insight, and less agitation and guilt than do elderly individuals who are depressed without vascular risk factors, on one hand, and also greater disability and cognitive impairment, on the other ([@b5]). Mast and coworkers reported vascular depression in nearly 35% (35.2%) of patients with cerebrovascular risk factors admitted in geriatric rehabilitation, but without clinical evidence of stroke ([@b57]). In that study, a positive association was established between depression and increasing percentage of cerebrovascular risk factors ([@b57]). Furthermore, patients with depression and subcortical vascular lesions have poor response to antidepressants ([@b77]), while might be effective dopamine acting agents or norepinephrine enhancing agents ([@b3]). Thus, should vascular depression be recognized as a separate psychiatric disorder or as a diagnostic subtype of major depressive disorder? Indeed, Alexopoulos refined the notion of vascular depression, proposing a depression executive dysfunction (DED) disorder of late-life, but only on the basis of clinical criteria and regardless the etiology ([@b2]), while [@b81] proposed subcortical ischemic depression as specific entity. On the other hand, while the former may be caused by vascular disease, the latter requires a subcortical vascular impairment. Further researches are needed to clarify these and other doubts.

Treatment studies
=================

Although antidepressant (AD) drugs have been discovered many decades ago \[monoamine oxidase inhibitors (MAOIs) in the 1950s, tricyclic antidepressant (TCA) imipramine in 1957 and first selective serotonin reuptake inhibitor (SSRI), fluoxetine in 1988\], most patients today do not receive an effective specific treatment. The attitude that PSD is a natural and inevitable condition which is not important to treat seems still common. General opinion appears to be that depression improves if the patient's physical condition improves ([@b32]). Moreover, physicians are often reluctant to prescribe ADs to older patients with relevant physical illnesses ([@b39]), because of the perceived risk of side effects especially on the cardiovascular system, fear of drug interactions in multiple comorbidity, and poor experience of depression treatment in the elderly. However, a recent systematic review of 18 randomized controlled trials comparing any AD drug with placebo or no treatment in depressed adults with a specified physical disorder showed that ADs cause improvement in depressive symptoms in patients with a wide range of physical diseases ([@b28]). In spite of these data, not only the studies on therapeutic approaches on PSD are relatively scarce, but also most of studies reported the effects of AD drugs only on mood disturbance. In fact, even if some authors suggested the favorable effect of AD drugs on functional recovery ([@b24]), there are only few studies that evaluated the impact of ADs on functional outcome and rehabilitation results ([@b71]; [@b24]; [@b30]; [@b21]; [@b59]; [@b64]; [@b27]; [@b63]).

[Table 2](#tbl2){ref-type="table"} reports the percentages of patients treated with ADs in papers regarding prevalence and clinical impact of PSD.

###### 

Percentages of patients treated with antidepressant in studies on prevalence of PSD

  Authors                  n       Population                      Country       \% patients treated
  ------------------------ ------- ------------------------------- ------------- ---------------------
  [@b78]                   64      Rehab hosp                      CND           33
  Ebrahim et al 1987       149     hospital-based                  UK            15
  Parikh et al 1990        63      hospital-based                  USA           8
  [@b37]                   150     hospital-based                  Canada        19
  Pohjasvaara et al 1998   277     hospital-based                  FIN           39
  [@b49]                   321     community                       FIN           17
  [@b43]                   106     rehab hosp                      FIN           36
  [@b64]                   470     rehab hosp                      Italy         100
  [@b84]                   85      rehab hosp                      Netherlands   20
  Eriksson et al 2004      15747   community                       Sweden        49
  Cassidy et al 2004       50      rehab hosp                      Ireland       60
  Paul et al 2006          441     outpatient                      Australia     22
  [@b65]                   1064    hospital-based                  Italy         49
  Jia et al 2006           5825    hospital-based, retrospective   USA           63

The choice of optimal treatment
===============================

There is relatively little comparative information on how to make the choice of one AD over another, and none at all specific to PSD. Today, SSRIs are the recommended pharmacotherapy of PSD for their favorable tolerability profile ([@b83]; [@b80]). In fact, the affinity of TCAs for a number of central receptors including muscarinic cholinergic and histaminergic receptors makes them not recommended as first-line choice for treatment of PSD. Conversely, SSRIs have no affinity for cholinergic or histaminergic receptors and thus are generally well tolerated, and do not have cardiovascular or sedative effects. However, the SSRIs are not entirely without side-effects. Gastrointestinal symptoms, headache, sexual dysfunction and insomnia are relatively common. Arguably, the most important difference between the SSRIs lays in their potential to cause drug- drug interactions through inhibition of cytochrome-P450 isoforms, which is different for each SSRI. Thus, fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor; fluoxetine and paroxetine are potent CYP2D6 inhibitors; sertraline is a moderate CYP2D6 inhibitor; and citalopram has little effect on the major cytochrome-P450 isoforms ([@b36]). So, fluvoxamine (CYP1A2 inhibitor) can cause an increase of blood levels of theophyllin or caffeine, while paroxetine and fluoxetine (CYP2D6 inhibitors) an increase of concentration of TCAs or atypical antipsychotics. Knowledge of the CYP-isoforms involved in the metabolism of the co-administered drug may help clinicians to predict and avoid potentially dangerous drug- drug interactions. Expected interactions can usually be managed by appropriate dose adjustments and titration of the drug. Importantly, the use of SSRIs has been associated with increased risk of bleeding complications ([@b79]), possibly as a result of inhibition of platelet aggregation ([@b58]). However, in a recent systematic review, [@b68] observed that SSRI treatment had a very low rate of cerebrovascular adverse reactions. In particular, two case-control studies mentioned in that review showed no association between SSRI use and intracranial hemorrhage ([@b23]; [@b10]).

Nonpharmacological management
=============================

Today, the main therapeutic approach of PSD, and in particularly in subacute phase after stroke, is essentially pharmacological. In fact, a psychotherapeutic intervention is not only expensive in terms of staff time and expertise, but also requires several weeks before showing any clinical improvement. This delay may be critical for the outcome in a time-limited course of rehabilitation. Therefore, in the common clinical practice, AD treatment is the most realistic solution, with psychotherapeutic intervention reserved for those in whom ADs are either inappropriate or not tolerated. Regarding the effectiveness of psychotherapeutic interventions, methodological limitations in existing research prevent a conclusion as any psychological intervention has empirical support for its effectiveness ([@b31]; [@b48]). On the other hand, cognitive behavioral therapy has shown some promising results that make it worthy of further exploration ([@b53]; [@b52]).

Controlled pharmacological studies
==================================

Controlled studies on the effectiveness of ADs in PSD are relatively few, and they are essentially related to the use of TCAs or SSRIs ([Table 3](#tbl3){ref-type="table"}). Data on usefulness of new dual-component ADs are still not available, to our knowledge.

###### 

Controlled studies on treatment of post-stroke depression

  Authors               No    Treatment studied                               Design   Time from stroke   Trial length   Outcome measures      Results
  --------------------- ----- ----------------------------------------------- -------- ------------------ -------------- --------------------- -----------------------------------------------------------------------------------------------------------
  [@b55]                34    nortryptiline vs placebo                        DB       ≤18 m              4--6 w         HDRS, ZSRDS           nortriptyline more effective than placebo in reduction of depression
  [@b71]                27    trazodone vs placebo                            DB       6 w                \~4--5 w       ZSRDS                 trazodone trend towards better functional status
  Andersen et al 1994   66    citalopram vs placebo                           DB       2--52 w            16 w           HDRS                  citalopram more effective than placebo in reduction of depression
  [@b51]                20    Imipramine+mianserin vs desipramine+mianserin   DB       \<3 m              6 w            HDRS                  Imipramine + mianserin more effective than desipramine + mianserin in reduction of depression
  [@b72]                56    nortryptiline vs fluoxetine vs placebo          DB       4--16 w            12 w           HDRS                  nortriptyline produced a significantly higher response rate than fluoxetine or placebo
  [@b88]                31    fluoxetine vs placebo                           DB       \<3 m              6 w            MADRS                 fluoxetine more effective than placebo in reduction of depression
  [@b26]                54    fluoxetine vs placebo                           DB       \<2 w              3 m            HDRS, BDI             fluoxetine more effective than placebo at 18-month follow-up evaluation
  [@b70]                74    citalopram vs reboxetina                        DB       \<12 m             16 w           HDRS, BDI             citalopram better in anxious depressed patients, reboxetine more effective in retarded depressed patients
  [@b61]                123   sertraline vs placebo                           DB       3 d -- 1y          26 w           MADRS, EDS            sertraline superior only in emotional distress, emotionalism and QoL
  [@b19]                152   fluoxetine vs placebo                           DB       14 m               3 m            BDI, clinical, STAS   fluoxetine more efficacious only in the treatment of emotional incontinence and anger proneness.

**Abbreviations:** w, weeks; m, months; y, years; DB, double-blind; BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery Asberg Depression Rating Scale; QoL, Quality of Life; STAS, Spielberger Trait Anger Scale.

In a recent Cochrane review, only 7 trials with AD, with a total of 615 patients, entered the meta-analyses ([@b33], [@b34]). The results of meta-analyses showed that there was evidence of a improvement in depression rating scales, but not in terms of a complete remission of depression following stroke ([@b33], [@b34]). However, some methodological aspects of this review have been criticized. In particular, [@b17] suggested that the overall effects of AD treatment in term of various depression scores would better be estimated by separating the pretreatment and post-treatment instead of calculating the mean differences. In this fashion, AD treatments were effective in patients after the stroke in term of reducing the symptoms of depression. Moreover, can the concept of remission be applied in patients with depression in comorbidity? In fact, the idea of remission refers to a return to symptom-free state or premorbid levels of functioning ([@b11]). Such a model for depression in comorbidity is obviously arduous to obtain, because of the presence of somatic symptoms.

In another recent review, involving six pharmacological studies, there was evidence that ADs significantly improved mood, also in spite of a relevant number of dropouts due to side effects treatment, especially with heterocyclic ADs ([@b13]). So, it appears that both TCAs and SSRIs may be effective in the treatment of PSD, although the latter may produce fewer side-effects.

Two randomized, double-blinded, placebo-controlled studies have evaluated the effectiveness of nortriptyline, a tricyclic drug ([@b55]; [@b72]). In the last one, the effectiveness of fluoxetine was also assessed ([@b72]). In both studies, a significant improvement in depression symptoms was observed in the treated groups as compared to controls. In particular, in the first study a mean baseline to endpoint improvement in HDRS score of 79% was observed in patients treated with nortriptyline as compared with an improvement of 40% in patients treated with placebo ([@b55]). In the second study, the mean improvement in HDRS score was higher in depressed patients treated with nortriptyline (60% vs. 9% for patients treated with fluoxetine and 30% with placebo) ([@b72]). Furthermore, in the study by [@b72], but not in that by [@b55], a better recovery in activities of daily living for nortriptyline group was observed. However, there was disagreement regarding drop-out rate: higher among those treated with nortriptyline (38%) in the study by [@b55], and among those treated with fluoxetine (40%) in the study by [@b72]. However, in this latter study, such high drop-outs rate with fluoxetine might have been due to the relative high dose (up to 40 mg per day) of fluoxetine used ([@b72]). Moreover, the results of this study fostered the discussion about methodological problems ([@b85]).

Two double-blinded controlled studies have assessed the effectiveness of citalopram, a selective serotonin reuptake inhibitors (SSRI), the first one vs. placebo and the second one vs. noradrenergic drug reboxetine ([@b7]; [@b70]). In both studies, citalopram showed good efficacy and tolerability. In the first study, a mean baseline to endpoint improvement in HDRS score of 45.5% was observed in patients treated with citalopram as compared with an improvement of 16% in patients treated with placebo. Although the drop-out rate was higher in citalopram group, the reported side effects were relatively well tolerated and transient ([@b7]). In the second trial, Rampello et al showed that citalopram exhibited greater efficacy in anxious depressed patients, while reboxetine was more effective in retarded depressed patients. No severe side effects were recorded during the study. The drop-out rate was similar between groups, too (three for both treatment) ([@b70]).

Four studies evaluated the effectives of fluoxetine, another SSRI agent, both on early and late phase after stroke ([@b72]; [@b88]; [@b26]; [@b19]). The results of these studies are conflicting. In particular, while a positive action on mood even in early phase was observed by [@b88], with a mean improvement in MADRS score of 58% for fluoxetine group vs. 31% in placebo group, [@b26] observed such positive action only in the follow-up. Moreover, [@b19] found that fluoxetine was effective only on emotional incontinence and anger proneness, while [@b72] above described a lower effectiveness in comparison with nortriptyline. The drop-out rates were also conflicting: Fruehwald observed no drop-outs during the treatment, Wiart only two (13.3%) in patients treated with fluoxetine, while Choi-Kwon 19.7% in fluoxetine group and 15.8% in placebo group ([@b88]; [@b26]; [@b19]).

Sertraline, another SSRI AD, showed no advantage in comparison to placebo either on major depressive episode or minor depressive disorder ([@b61]). In fact, both groups improved substantially, with no differences between the treatments, either for major depressive episode or minor depressive disorder, or for short- or long-term antidepressant effect and neurologic outcome. However, the compound showed a significantly positive effect only on QoL at follow-up at week 26. No serious side effects were observed ([@b61]).

A study by [@b51] compared the efficacy of two TCAs, desipramine against imipramine, both drugs combined with mianserin. The doses of the drugs were flexible, with side-effects as a guide during treatment. Imipramine treatment was more effective than desipramine in reducing depressive symptoms evaluated by means of Melancholia Scale, but not by means of HDRS. However, a large proportion (35%) of the sample was lost in the follow-up, particularly in the desipramine group ([@b51]).

Lastly, [@b71] evaluated the response of depressive symptoms to trazodone in a controlled trial vs. placebo. They showed that trazodone treated patients had a tendency to increase in autonomy in ADL measured by the Barthel index compared to patients treated with placebo. However, a high drop-out rate due to side effects was observed in both groups of patients. In particular, twelve patients discontinued the study: six patients from the trazodone group (4 sedation, 1 eye discomfort, 1 refusal), but also six patients in placebo group (4 sedation, 1 nausea, 1 dizziness). Moreover, because of the particular study design, it was not possible to compare the improvement in depression scores of both groups.

Other studies
=============

There are other studies that evaluated the impact of different type of ADs on functional outcome and rehabilitation results. Today, AD therapy may be beneficial to functional recovery but it cannot abolish the detrimental effect of depression on functional outcome ([@b30]; [@b21]; [@b59]; [@b27]).

In a nonrandomized study published in 1995, Gonzalez-Torrecillas and colleagues showed that treated PSD patients (with nortriptyline or fluoxetine) had not only a better mood, but also a better functional and cognitive outcome compared to untreated PSD patients. Moreover, the study was nonblinded: fluoxetine was given to patients with cardiac defects and nortriptyline to those without. Both drugs made similar gains in both mood and functional ability ([@b30]).

Some years later [@b27] confirmed that functional recovery of nontreated depressed patients was poorer than the nondepressed and the depressed but treated patients.

[@b21] observed that patients treated with fluoxetine had better rehabilitation results in comparison with those of patients treated with norepinephrine reuptake blocker maprotiline or placebo. These effects were not related to the specific antidepressant action. Moreover, both groups treated with Ads showed a significant baseline to endpoint mean improvement in HDRS score (fluoxetine 30%, maprotiline 18%). Mean improvement in placebo group was 12%.

This favorable role of fluoxetine on functional status was confirmed also by another study, in which patients treated with fluoxetine or trazodone showed a better improvement on functional independence measure compared with patients treated with desipramine ([@b59]).

Since serotonin (5-HT) stimulates motor function, there are some studies that investigated the hypothesis that a pharmacological potentiation of 5-HT neurotransmission may improve motor function in healthy subjects and recovery in poststroke patients ([@b66]; [@b56]). In particular, in a double-blind, crossover, placebo-controlled study on 8 patients with pure motor hemiparesis, a single dose of fluoxetine was able to significantly improve motor skills of the affected side ([@b66]). However, other experimental reports (after focal ischemia in rats) did not confirm these adjuvant action of fluoxetine on recovery of motor function ([@b90]).

ADs may reduce post stroke mortality. In a 9 year follow-up study, treatment with fluoxetine or nortriptyline for 12 weeks during the first 6 months after stroke significantly increased the survival of both depressed and nondepressed patients ([@b41]).

Lastly, there are few studies on the usefulness of new dual-agents SNRIs (serotonin and norepinephrine reuptake inhibitors), as venlafaxine or milnacipran and duloxetine ([@b20]; [@b91]), but methodological problems (open-label studies and with small case-series) reduce the power of these data.

Prevention of PSD
=================

A recent Cochrane review, evaluating data from nine trials (11 comparisons) involving different pharmaceutical agents, and three trials of psychotherapy, found no clear effect of either pharmacotherapy or psychotherapy on the prevention of depressive illness or disability ([@b9]). Moreover, data from a more recent trial showed that sertraline treatment, 50 mg/day, had no advantage in comparison to placebo in preventing PSD ([@b6]).

A more recent meta-analysis published in 2007, evaluating 10 randomized clinical trials, with a total of 703 nondepressed stroke patients, found that ADs prophylaxis was associated with a significant reduction in the occurrence rate of newly developed poststroke depression (12.54% in the treated group vs 29.17% in control group) ([@b18]).

Length of treatment
===================

At present, there is no scientific evidence regarding the optimal length of treatment of PSD. Many of the available trials terminate at six weeks, but withdrawal at this stage may result in relapse. In a recent review, [@b83] recommended carrying on AD treatment for 4--6 months, followed by slow withdrawal. The same length of AD is recommended by the Italian Guidelines for stroke management SPREAD (Stroke Prevention and Awareness Diffusion), but the power of this recommendation is weak (grade GPP, based on the clinical experience of the guideline development group, without research evidence) ([@b80]).

Conclusions
===========

Presently, there are still too many questions about PSD and too few answers. Crucial unresolved issues are essentially related to correct diagnostic and therapeutic approaches. There is clear evidence that an AD treatment may improve depression but it is unable to produce a full clinical remission or prevent the onset of diagnosable depressive illness. Moreover, data available regarding the choice or the length of optimal treatment are still not conclusive.

Because the benefits of AD therapy are potentially great, not only on mood but also on functional recovery, there is a pressing need for further research in this area of stroke medicine.
